Beam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare Conference
Beam Therapeutics (Nasdaq: BEAM), a biotechnology company focused on developing precision genetic medicines through base editing, has announced its upcoming participation in the 2025 RBC Capital Markets Global Healthcare Conference. The company's management will engage in a fireside chat on Tuesday, May 20, 2025, at 11:00 a.m. ET in New York. Investors and interested parties can access the live webcast through Beam's website investor section at www.beamtx.com, where it will remain archived for 60 days after the presentation.
Beam Therapeutics (Nasdaq: BEAM), un'azienda biotecnologica specializzata nello sviluppo di terapie genetiche di precisione tramite base editing, ha annunciato la sua partecipazione alla 2025 RBC Capital Markets Global Healthcare Conference. Il management della società parteciperà a una conversazione informale il martedì 20 maggio 2025 alle 11:00 ET a New York. Investitori e interessati potranno seguire la diretta streaming attraverso la sezione investitori del sito web di Beam all'indirizzo www.beamtx.com, dove la registrazione resterà disponibile per 60 giorni dopo la presentazione.
Beam Therapeutics (Nasdaq: BEAM), una empresa biotecnológica centrada en el desarrollo de medicamentos genéticos de precisión mediante edición de bases, ha anunciado su próxima participación en la Conferencia Global de Salud RBC Capital Markets 2025. La dirección de la compañía participará en una charla informal el martes 20 de mayo de 2025 a las 11:00 a.m. ET en Nueva York. Los inversores e interesados podrán acceder a la transmisión en vivo a través de la sección de inversores del sitio web de Beam en www.beamtx.com, donde quedará archivada durante 60 días tras la presentación.
Beam Therapeutics (나스닥: BEAM)는 베이스 에디팅을 통한 정밀 유전자 치료제 개발에 집중하는 생명공학 회사로, 2025 RBC Capital Markets 글로벌 헬스케어 컨퍼런스에 참가할 예정임을 발표했습니다. 회사 경영진은 2025년 5월 20일 화요일 오전 11시(동부시간) 뉴욕에서 진행되는 파이어사이드 채팅에 참여합니다. 투자자 및 관심 있는 분들은 Beam 웹사이트 투자자 섹션(www.beamtx.com)을 통해 라이브 웹캐스트를 시청할 수 있으며, 발표 후 60일간 아카이브로 제공됩니다.
Beam Therapeutics (Nasdaq : BEAM), une société de biotechnologie spécialisée dans le développement de médicaments génétiques de précision via l'édition de bases, a annoncé sa prochaine participation à la conférence mondiale sur la santé RBC Capital Markets 2025. La direction de l'entreprise participera à une discussion informelle le mardi 20 mai 2025 à 11h00 ET à New York. Les investisseurs et parties intéressées pourront accéder à la diffusion en direct via la section investisseurs du site web de Beam à l'adresse www.beamtx.com, où elle restera archivées pendant 60 jours après la présentation.
Beam Therapeutics (Nasdaq: BEAM), ein Biotechnologieunternehmen, das sich auf die Entwicklung präziser genetischer Medikamente durch Basenediting spezialisiert hat, hat seine bevorstehende Teilnahme an der 2025 RBC Capital Markets Global Healthcare Conference angekündigt. Das Management des Unternehmens wird am Dienstag, den 20. Mai 2025, um 11:00 Uhr ET in New York an einem Fireside-Chat teilnehmen. Investoren und Interessierte können den Live-Webcast über den Investorenbereich der Beam-Website unter www.beamtx.com verfolgen, wo er nach der Präsentation 60 Tage lang archiviert bleibt.
- None.
- None.
CAMBRIDGE, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in a fireside chat at the 2025 RBC Capital Markets Global Healthcare Conference on Tuesday, May 20, 2025, at 11:00 a.m. ET in New York.
The live webcast will be available in the investor section of the company's website at www.beamtx.com and will be archived for 60 days following the presentation.
About Beam Therapeutics
Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform with integrated gene editing, delivery and internal manufacturing capabilities. Beam’s suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases.
Contact:
Holly Manning
Beam Therapeutics
hmanning@beamtx.com
FAQ
When is Beam Therapeutics (BEAM) presenting at the 2025 RBC Capital Markets Healthcare Conference?
Where can I watch Beam Therapeutics' (BEAM) presentation at the RBC Healthcare Conference?
What type of company is Beam Therapeutics (BEAM)?
How long will Beam Therapeutics' (BEAM) RBC Conference presentation be available online?
